United Therapeutics Corporation

NasdaqGS:UTHR Stock Report

Market Cap: US$18.3b

United Therapeutics Valuation

Is UTHR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UTHR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UTHR ($400.44) is trading below our estimate of fair value ($999.87)

Significantly Below Fair Value: UTHR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UTHR?

Other financial metrics that can be useful for relative valuation.

UTHR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.1x
Enterprise Value/EBITDA10x
PEG Ratio2x

Price to Earnings Ratio vs Peers

How does UTHR's PE Ratio compare to its peers?

The above table shows the PE ratio for UTHR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.9x
BMRN BioMarin Pharmaceutical
39.2x27.3%US$12.8b
NBIX Neurocrine Biosciences
33.4x29.9%US$12.7b
HZNP Horizon Therapeutics
60.8x16.4%US$26.6b
EXEL Exelixis
22.1x15.6%US$10.4b
UTHR United Therapeutics
16.1x8.1%US$18.3b

Price-To-Earnings vs Peers: UTHR is good value based on its Price-To-Earnings Ratio (16.1x) compared to the peer average (31.6x).

Price to Earnings Ratio vs Industry

How does UTHR's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.3%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.3%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: UTHR is good value based on its Price-To-Earnings Ratio (16.1x) compared to the US Biotechs industry average (16.5x).

Price to Earnings Ratio vs Fair Ratio

What is UTHR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UTHR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.1x
Fair PE Ratio25.3x

Price-To-Earnings vs Fair Ratio: UTHR is good value based on its Price-To-Earnings Ratio (16.1x) compared to the estimated Fair Price-To-Earnings Ratio (25.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UTHR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$400.44
US$382.29
-4.5%
21.1%US$600.00US$221.00n/a14
Nov ’25US$374.02
US$382.29
+2.2%
21.1%US$600.00US$221.00n/a14
Oct ’25US$357.83
US$356.52
-0.4%
23.1%US$575.00US$221.00n/a14
Sep ’25US$363.55
US$350.71
-3.5%
23.6%US$575.00US$221.00n/a13
Aug ’25US$327.79
US$332.79
+1.5%
15.9%US$400.00US$221.00n/a13
Jul ’25US$319.01
US$302.52
-5.2%
15.2%US$400.00US$221.00n/a14
Jun ’25US$275.13
US$294.16
+6.9%
15.5%US$400.00US$220.00n/a14
May ’25US$255.14
US$287.69
+12.8%
14.9%US$375.00US$218.00n/a15
Apr ’25US$228.26
US$287.33
+25.9%
16.3%US$375.00US$183.00n/a16
Mar ’25US$231.92
US$286.13
+23.4%
16.0%US$375.00US$183.00n/a16
Feb ’25US$215.97
US$284.08
+31.5%
17.3%US$375.00US$178.00n/a14
Jan ’25US$219.89
US$284.08
+29.2%
17.3%US$375.00US$178.00n/a14
Dec ’24US$240.73
US$281.88
+17.1%
17.9%US$375.00US$177.00n/a13
Nov ’24US$224.08
US$282.12
+25.9%
17.9%US$375.00US$177.00US$374.0213
Oct ’24US$225.87
US$278.82
+23.4%
19.9%US$375.00US$170.00US$357.8311
Sep ’24US$228.05
US$278.82
+22.3%
19.9%US$375.00US$170.00US$363.5511
Aug ’24US$240.13
US$275.73
+14.8%
21.1%US$375.00US$160.00US$327.7911
Jul ’24US$220.75
US$274.82
+24.5%
21.0%US$375.00US$160.00US$319.0111
Jun ’24US$213.48
US$275.15
+28.9%
19.3%US$375.00US$160.00US$275.1313
May ’24US$232.11
US$278.92
+20.2%
19.7%US$375.00US$150.00US$255.1413
Apr ’24US$223.96
US$281.62
+25.7%
19.7%US$375.00US$150.00US$228.2613
Mar ’24US$244.89
US$281.85
+15.1%
19.7%US$375.00US$150.00US$231.9213
Feb ’24US$259.99
US$279.92
+7.7%
19.9%US$375.00US$150.00US$215.9713
Jan ’24US$278.09
US$278.00
-0.03%
19.7%US$375.00US$150.00US$219.8913
Dec ’23US$275.61
US$277.82
+0.8%
20.0%US$375.00US$150.00US$240.7311
Nov ’23US$228.39
US$248.73
+8.9%
17.3%US$325.00US$142.00US$224.0811

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y